JNJ TECVAYLI + TALVEY Cuts Myeloma Risk 89%

Johnson & Johnson (JNJ) closed at $259.27 on July 22, 2026. The stock has climbed from $223.51 in early June to $259, a 16% gain over seven weeks. Polygon data shows the run started before the MonumenTAL-6 readout. The market is pricing in good news. It is pricing in the wrong good news.

On July 23, J&J announced Phase 3 MonumenTAL-6 results for TECVAYLI (teclistamab) plus TALVEY (talquetamab) in relapsed/refractory multiple myeloma. The numbers are not incremental. An 89% PFS reduction in a Darzalex-refractory population is the lowest hazard ratio any bispecific has posted in a Phase 3 myeloma trial.

The trial

MonumenTAL-6 is a three-arm Phase 3 study in patients with relapsed/refractory multiple myeloma who received 1 to 4 prior lines of therapy, including an anti-CD38 antibody and lenalidomide. Roughly 80% of patients were refractory to DARZALEX, J&J’s own $14.4 billion-per-year CD38 antibody. These are hard-to-treat patients.

The TECVAYLI + TALVEY arm (Tec-Tal) reduced the risk of disease progression or death by 89% compared to investigator’s choice standard of care (hazard ratio 0.11, 95% CI 0.08-0.16, p<0.0001). The risk of death fell 62% (HR 0.38). A second investigational arm, TALVEY plus pomalidomide (Tal-P), showed a 73% PFS reduction (HR 0.27, 95% CI 0.2-0.35).

An 89% risk reduction is not a marginal win. It is the lowest hazard ratio seen across any Phase 3 bispecific study in relapsed/refractory myeloma. The press release from PRNewswire confirmed both arms met the primary PFS endpoint with statistical significance.

Why dual targeting matters

TECVAYLI is a BCMAxCD3 bispecific antibody. TALVEY is a GPRC5DxCD3 bispecific antibody. Both are already approved as monotherapies for later lines of myeloma. The idea behind combining them is simple: myeloma cells express both BCMA and GPRC5D surface proteins. Targeting both antigens simultaneously hits the cancer from two directions, making it harder for the cancer to escape through antigen loss.

This is the same logic that drove CAR-T therapy development in B-cell malignancies, where CRISPR Therapeutics is engineering next-generation cell therapies. But bispecifics have one enormous practical advantage: they are off-the-shelf. No cell manufacturing. No apheresis. No weeks-long wait for a personalized product. A patient walks into a clinic and gets a subcutaneous injection.

The comparison to CAR-T is the core investment question here. J&J’s own CAR-T therapy, Carvykti (partnered with Legend Biotech), showed a 59% PFS improvement in the Phase 3 Cartitude-4 trial in second-line or later myeloma. MonumenTAL-6’s Tec-Tal combo produced an 89% PFS reduction. Direct cross-trial comparisons are imperfect, but the magnitude of difference is large enough to matter. If bispecific combinations can match or beat CAR-T efficacy without the manufacturing bottleneck, the standard of care changes.

The competitive picture

J&J dominates multiple myeloma. DARZALEX generated $14.4 billion in 2025 sales, making it the company’s biggest product by far. TECVAYLI is projected to reach $1.8 billion by 2031, per analyst estimates cited by Clinical Trials Arena. Carvykti nearly doubled to $1.9 billion in 2025. Add TALVEY to the mix and J&J has three myeloma franchises targeting different mechanisms.

The competitors are real but trailing. Bristol Myers Squibb (BMY) markets Reblozyl and has its own cell therapy pipeline. Pfizer has Elrexfio (elranatamab), another BCMA bispecific. Regeneron recently launched Lynozyfic (linvoseltamab). But none of them have a dual-targeting bispecific combination with Phase 3 survival data. J&J is the only company testing BCMA plus GPRC5D together.

Like Gilead’s lenacapavir in HIV, a single dominant product can redefine a company’s growth trajectory. J&J is pursuing the same strategy in myeloma, layering TECVAYLI and TALVEY on top of DARZALEX to create a multi-product franchise that competitors cannot easily replicate.

The global multiple myeloma market was estimated at $16.4 billion in 2023 and is projected to reach $38 billion by 2034. J&J’s DARZALEX alone captured $14.4 billion last year. If TECVAYLI + TALVEY gains a label expansion into earlier lines based on MonumenTAL-6, J&J’s share of that growing market expands further.

Valuation

At $259.27 per share, J&J has a market cap of $615 billion. The stock trades at roughly 22 times forward earnings. That is a premium multiple for a company expected to grow revenue at 7-8% annually. The oncology portfolio generated $25.4 billion in 2025, and J&J targets $50 billion in oncology sales by 2030.

The comp that matters is Bristol Myers Squibb. BMY trades at roughly 8 times forward earnings with a market cap around $85 billion. BMY faces patent cliffs on Revlimid and Pomalyst, the foundational myeloma drugs that J&J’s bispecifics are designed to replace. The valuation gap between J&J and BMY reflects J&J’s pipeline depth and franchise dominance. It is justified.

But here is the issue: at 22x earnings, J&J is priced for execution. MonumenTAL-6 is a major catalyst, but the stock moved 16% in the seven weeks before the announcement. The market already ran the stock up on Q2 earnings and DARZALEX momentum. The bispecific data is incremental upside that the current price does not fully reflect, but the easy money has been made.

The risk

The specific risk is safety and label expansion timing. MonumenTAL-6 enrolled patients who had already received 1 to 4 prior lines. Moving bispecific combinations into earlier lines requires the FDA to accept the risk-benefit calculus in less heavily pretreated patients. The safety profile was described as consistent with known monotherapy profiles, which means cytokine release syndrome, infections, and neurotoxicity remain concerns. The press release noted fewer infections than historically observed with TECVAYLI monotherapy, which is encouraging. But broader use means broader exposure to these risks.

The next catalyst is a regulatory submission for the Tec-Tal combination. J&J has not announced a filing date. If the FDA requires additional safety data or an advisory committee, the timeline stretches into 2027. Meanwhile, Carvykti is already approved in earlier lines and generating $1.9 billion annually. The window for bispecific combinations to capture earlier-line patients is narrowing as CAR-T manufacturing improves.

The verdict

The MonumenTAL-6 data produced an 89% PFS reduction with a 62% overall survival benefit in a Darzalex-refractory population. The prior best bispecific Phase 3 result in myeloma was teclistamab monotherapy in MajesTEC-1, which showed a 63% overall response rate in heavily pretreated patients but no randomized PFS comparison. MonumenTAL-6 is the first randomized Phase 3 to show a survival benefit for a bispecific combination. J&J’s myeloma franchise spans three approved products: DARZALEX ($14.4B in 2025 revenue), TECVAYLI, and TALVEY, plus Carvykti ($1.9B in 2025). No competitor has more than one approved bispecific in this disease.

But at $259 and 22x earnings, J&J is not cheap. The 16% run-up in the stock ahead of this data tells me the market was already pricing in a strong readout. For investors who already own J&J, the data confirms the thesis: this is the best-positioned large-cap pharma in oncology. For new buyers, the entry point is mediocre. I would wait for a pullback to $245-250 before adding. The data supports a higher price, but the stock has already moved.

The deeper question is whether bispecific combinations will cannibalize Carvykti, J&J’s own CAR-T product. If Tec-Tal can deliver 89% PFS reductions off the shelf, why would a physician wait weeks for a CAR-T manufacturing process? J&J is betting both sides of this trade, and so far, that bet looks smart. The company that owns the standard of care in myeloma, whether it is a bispecific or a CAR-T, wins. Right now, that company is J&J.